share_log

アステラス製薬:日本の厚生労働省は、根治的に切除不能な尿路上皮がんの第一選択治療薬としてPADCEVとKEYTRUDAを承認しました

Astellas Pharma: Japan’s Ministry of Health, Labour and Welfare Approves PADCEV with KEYTRUDA for First-Line Treatment of Radically Unresectable Urothelial Carcinoma

JPX ·  Sep 24, 2024 14:00

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.